Get the Stockscreener App
33.92
1.22%
0.41
Korsana Biosciences, Inc. Common Stock stock is traded at $33.92, with a volume of 45,916.
It is up +1.22% in the last 24 hours and up +29.47% over the past month.
See More
Previous Close:
$33.51
Open:
$33.5
24h Volume:
45,916
Relative Volume:
0.60
Market Cap:
$1.54B
Revenue:
Net Income/Loss:
P/E Ratio:
-
EPS:
-
Net Cash Flow:
1W Performance:
+11.25%
1M Performance:
+29.47%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$29.93
$35.34
52-Week Range:
$21.00
$37.27
Korsana Biosciences, Inc. Common Stock Stock (KRSA) Company Profile
Name
Korsana Biosciences, Inc. Common Stock
Sector
Industry
Phone
-
Address
-
Compare KRSA vs VRTX, MRNA, REGN, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KRSA
Korsana Biosciences, Inc. Common Stock
|
33.92 | 1.54B | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
510.08 | 129.29B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
225.00 | 89.83B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
746.54 | 76.86B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
825.03 | 51.88B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.76 | 40.67B | 742.00K | -1.37B | -1.07B | -7.0731 |
Korsana Biosciences, Inc. Common Stock Stock (KRSA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-05-26 | Initiated | Wedbush | Outperform |
| Sep-28-26 | Initiated | Guggenheim | Buy |
| Sep-14-26 | Initiated | Stifel | Buy |
| Sep-14-26 | Initiated | TD Cowen | Buy |
| Sep-11-26 | Initiated | UBS | Buy |
| Oct-20-21 | Initiated | Truist | Buy |
| Sep-24-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-03-19 | Initiated | Credit Suisse | Neutral |
View All
Korsana Biosciences, Inc. Common Stock Stock (KRSA) Latest News
A passive stake above 5% in Korsana Biosciences (KRSA) is reported by FMR LLC in an amendment. - Stock Titan
Korsana Biosciences (NASDAQ: KRSA) director to sell 100 more shares after 2,139 sold recently - Stock Titan
After two September sales, a Korsana Biosciences (KRSA) director proposes selling 4,903 more shares. - Stock Titan
General Atlantic’s stake in Korsana (CYCN) comes with a strict ownership cap - Stock Titan
Korsana Biosciences (CYCN) director proposes $74.8K stock sale - Stock Titan
A fund reports a 6.1% passive stake in Korsana Biosciences (CYCN), with the investor's identity detailed in the filing. - Stock Titan
Nearly 10% of Korsana Biosciences (CYCN) is tied to one investor group, but its ownership is capped below that line. - Stock Titan
Diluted net income available to common stockholders of Korsana Biosciences, Inc. – NASDAQ:KRSA - TradingView
Korsana Biosciences, Inc. Statistics – NASDAQ:KRSA - TradingView
Investor gains significant stake and board power at Korsana Biosciences (CYCN) - Stock Titan
Korsana Biosciences, Inc. (KRSA) Company Information - Simply Wall Street
Why a 9.99% cap now limits a key Korsana (CYCN) holder - Stock Titan
CFO option stakes detailed at Korsana Biosciences (CYCN) after merger - Stock Titan
Merger gives Korsana Biosciences (CYCN) CMO options expiring in 2036 - Stock Titan
Korsana Biosciences (CYCN) director holds merger-issued option - Stock Titan
New Korsana Biosciences (CYCN) director reports 28,805-share option - Stock Titan
Korsana Biosciences Completes Closing of Merger with Cyclerion Therapeutics and Previously Announced Private Placement of $380 Million - The Manila Times
CYCN Stock Explodes 313% on April 1 After Cyclerion-Korsana Merger Deal for Alzheimer's Pipeline - International Business Times Australia
Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement - Business Wire
Why is Biotech Stock Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) Gaining? - Investorideas.com
Cyclerion Therapeutics and Korsana Biosciences To Merge - citybiz
Cyclerion Therapeutics and Korsana Biosciences to merge - The Pharma Letter
CYCN Merges with Korsana Biosciences for Strategic Growth - GuruFocus
Korsana Biosciences, Inc. Common Stock Stock (KRSA) Financials Data
There is no financial data for Korsana Biosciences, Inc. Common Stock (KRSA). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Korsana Biosciences, Inc. Common Stock Stock (KRSA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| ERROL B DE SOUZA | Director |
Sep 22 '26 |
Proposed Sale |
34.99 |
100 |
3,499 |
0 |
| ERROL B DE SOUZA | Director |
Sep 18 '26 |
Proposed Sale |
34.99 |
2,139 |
74,844 |
0 |
| CHICKO RHONDA M. | Chief Financial Officer |
Aug 14 '26 |
Option Exercise |
2.35 |
25,000 |
58,875 |
25,018 |
| Graul Regina Margaret | See Remarks |
Aug 14 '26 |
Option Exercise |
3.30 |
55,849 |
184,302 |
156,152 |
1.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):